Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
CORCEPT THERAPEUTICS INC (CORT) received a Rule 144 notice for a proposed sale of up to 175,000 shares of common stock for the account of officer Sean Maduck, with Stifel Nicolaus & Company Inc listed as broker. The shares derive from stock option awards dated February 8, 2019 (100,000 shares) and February 10, 2017 (75,000 shares), categorized as equity compensation. Over the prior three months, Maduck reported sales totaling multiple tranches of common stock, including 75,000 shares on May 27, 2026 and several smaller sales through August 14, 2026.
Corcept Therapeutics Inc (CORT) director David L. Mahoney reported indirect sales of company common stock on August 18, 2026. A family trust associated with him sold a total of 103,606 shares in multiple open-market transactions at weighted average prices between $116.595 and $119.6775, pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. The filing also reports 26,147 shares of common stock held indirectly through The Black Dog Private Foundation.
CORCEPT THERAPEUTICS INC (CORT) officer Sean Maduck, President of Corcept Endocrinology, reported an option exercise and related sale on August 14, 2026. He exercised stock options for 3,664 shares of common stock at $8.27 per share and then sold 3,664 shares of common stock at $114.49 per share pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. Following the option exercise, he held 91,986 shares directly, which include unvested restricted stock awards, and also has indirect holdings through various trusts and entities as described in the ownership footnotes, with beneficial ownership of one entity disclaimed except for his pecuniary interest.
CORCEPT THERAPEUTICS INC (CORT) director James N. Wilson reported indirect sales of common stock on August 14, 2026 by the James N. Wilson and Pamela D. Wilson Trust. The trust sold a total of 10,000 shares in multiple open-market transactions at weighted average prices between about $110 and $113 per share, pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. Wilson has voting power over the trust’s shares but disclaims beneficial ownership except to the extent of his pecuniary interest. Separate indirect holdings entries report 200,000 shares of common stock in each of the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust.
CORCEPT THERAPEUTICS INC (CORT) reported insider transactions by Chief Business Officer Gary Charles Robb. On 2026-08-17, he made a bona fide gift of 125 common shares, leaving 13,426 shares held directly, which include multiple unvested restricted stock awards that vest one year after their grant dates, subject to conditions. The same day, an entity associated with him, the Gary Charles Robb TTE Robb Revocable Trust, sold 10,000 common shares at a weighted average price of $116.2572 per share (range $116.00–$116.54), resulting in 39,716 shares held indirectly through the trust. Additional shares are held in custodial accounts for his children under the Uniform Transfers to Minors Act, where he acts as custodian.
CORCEPT THERAPEUTICS INC (CORT) is the issuer for which director David L. Mahoney has filed a notice of proposed sale of restricted or control securities under Rule 144. The filing covers 103,606 shares of common stock held in a trust account titled “David L Mahoney & Winnifred C Ellis TR U/A DTD 06/25/1998, W Ellis & D Mahoney TTEE,” with The Charles Schwab Corporation listed as the broker. The shares were acquired through open market purchases between 05/22/2020 and 04/12/2024, and the notice is dated 08/18/2026, indicating an intention to sell these shares on the open market on or after that date, subject to Rule 144 conditions.
Corcept Therapeutics Inc’s Chief Business Officer, Gary Charles Robb, reported several bona fide gift transactions in the company’s common stock on August 12, 2026. He made a gift disposition of 11,530 shares, leaving 13,551 shares held directly, including unvested restricted stock awards. He also reported gifts of 3,000 shares to each of two custodial accounts for his children, which are reported as indirect holdings. Separately, an additional 49,716 shares are held indirectly through the Gary Charles Robb TTE Robb Revocable Trust.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of common stock of Corcept Therapeutics Inc. They state beneficial ownership of 5,261,628 shares of common stock, representing 4.90% of the class. The filing indicates sole voting and sole dispositive power over all 5,261,628 shares, with no shared voting or dispositive power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from the sale of these securities.
Corcept Therapeutics executive Sean Maduck exercised options for 1,031 shares of common stock at $8.27 per share and sold the same 1,031 shares at a weighted average price of $114.5182 on August 10, 2026. Following the option exercise, he held 95,650 stock options directly, and also holds various indirect positions through trusts and LLCs. The sale was executed under a Rule 10b5-1 trading plan adopted on December 8, 2025. His direct holdings include unvested restricted stock awards that vest one year after their respective grant dates.